Please login to the form below

Not currently logged in

Novo launches Victoza in China

Novo Nordisk has launched its type 2 diabetes treatment Victoza in China – an increasingly important market for diabetes products

Novo Nordisk has launched its type 2 diabetes treatment Victoza (liraglutide injection) in China.

The medicine, a glucagon-like peptide-1 (GLP-1) analogue, was approved by the Chinese regulatory authorities on March 15 as an add-on to metformin or sulphonylurea (SU) in people with insufficient glycaemic control despite taking the maximal tolerated dose of monotherapy with metformin or SU.

Diabetes is a significant area of growth in China's healthcare market, with over 43 million people in the country diagnosed with type 2 diabetes.

That figure is set to increase even more due to increased urbanisation of the country and the adoption of more Western lifestyles and diet, according to data from The Research Partnership.

Victoza has been shown to help lower blood sugar levels, reduce body weight, lower systolic blood pressure and shows improvements in measurements of beta cell function.

Data presented at the European Association for the Study of Diabetes (EASD) meeting in Lisbon in September 2011 also demonstrated the drug has greater benefit if used early in the treatment of type 2 diabetes.

Victoza is already marketed in more than 39 countries globally including the US, Japan and the EU.

Related links:

Case study: Diabetes in China
Country report: China

10th October 2011


Featured jobs

Subscribe to our email news alerts


Add my company

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...